

Product Data Sheet

Product Name: Vevorisertib tetrahydrochloride

Cat. No.: GC81892

Chemical Properties

Cas. No.

Formula $C_{35}H_{42}Cl_4N_8O$ M.Wt 732.57

Solubility DMSO: 100 mg/mL (136.51 mM; Need ultrasonic) Storage Store at 4°C, sealed storage, away from moisture

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

Vevorisertib tetrahydrochloride (ARQ 751 tetrahydrochloride) is an orally active allosteric AKT inhibitor that blocks AKT phosphorylation. Vevorisertib tetrahydrochloride inhibits tumor cell

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

proliferation through Cyclin D1 and Ki67. Vevorisertib tetrahydrochloride inhibits liver fibrosis through collagen accumulation, alpha-SMA, COL1, and TGF-beta. Vevorisertib tetrahydrochloride reduces total bilirubin. Vevorisertib tetrahydrochloride significantly reduces tumor size in a cirrhotic rat HCC model. Vevorisertib tetrahydrochloride can be used for research on hepatocellular carcinoma [1].

In Vivo, Vevorisertib (10 mg/kg/day; p.o.; daily; 15 days) tetrahydrochloride significantly reduces tumor size, decreases tumor number, inhibits tumor cell proliferation, and ameliorates liver fibrosis in the diethylnitrosamine (DEN)-induced cirrhotic rat HCC model[1].

In Vitro, Vevorisertib tetrahydrochloride completely blocks AKT (Ser473) phosphorylation in Hep3B, HepG2, HuH7, and PLC/PRF/5 cell lines at both IC20 and IC50 concentrations[1].

References:

[1]. Kurma K, et al. Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model. International journal of molecular sciences. 2022 Dec 19;23(24):16206.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA